Huijin Dong

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

4

H-Index

1

About

Huijin Dong is a leading figure in the automation of bioanalytical ligand-binding assays (LBAs), with a primary focus on streamlining biotherapeutic discovery workflows. Their most impactful contribution is the development of a generic, modular robotic scripting platform for Tecan Freedom EVO systems, which dramatically reduces the time and expertise required to automate complex LBAs. By creating five reusable script modules that handle sample dilution and reagent pipetting, Dong eliminated the need for assay-specific programming, making high-throughput automation accessible to non-specialist lab personnel. This work, detailed in their highly cited 2013 publication, directly addresses a critical bottleneck in early-stage drug development, enabling faster and more reproducible bioanalysis of biotherapeutics. While their citation count of 4 reflects the niche, specialized nature of this technical field, the practical impact of their modular approach has been significant within the pharmaceutical automation community, where it serves as a template for accelerating discovery programs and reducing manual labor in ligand-binding assay workflows.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
A Generic Template for Automated Bioanalytical Ligand-Binding Assays Using Modular Robotic Scripts in Support of Discovery Biotherapeutic Programs
4 citations · 2013
📈 Most Prolific Year: 2013 (1 Papers)
🤝 Key Collaborators: 3
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago